Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences' PCT Platform Published in 2018Press Release | 01/24/2019
Over 20 Journal Articles Describe the Advantages of the PCT Platform in Multiple Areas of Research, Including Cancer, Biomarker Discovery, and Food Safety
SOUTH EASTON, MA / ACCESSWIRE / January 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that more than 20 scientific papers citing the advantages of the Company's pressure cycling technology ("PCT" platform were published by independent researchers worldwide in 2018. The publications, authored by scientists from academia, government, and industry, described a wide range of enabling applications for PBI's patented PCT Platform in cancer research, biomarker discovery, and food safety, as well as in proteomic and molecular biology studies.
In 2018, a record number of scientific papers highlighting the advantages of PCT over competitive methods were published, authored by researchers in North America, Europe, and Asia. Importantly, a number of these papers were written by scientists considered by many in the life sciences as Key Opinion Leaders ("KOLs" in their field. High quality papers authored by independent scientists - especially KOLs - and published in well-known, respected journals are an integral part of PBI's marketing strategy.
Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "We know that scientists have a strong tendency to rely heavily on data and opinions from colleagues and other experts in their field. We therefore enhanced our marketing efforts during the second half of 2018 with a concerted effort to forward this large number of scientific publications to our base of existing and potential customers.We were pleased to see this effort result in increased interest and sales of our Barocycler instruments in 2018, which we believe will continue into 2019 as well."
The 2018 publications were primarily in the following key areas.
Cancer Research
Six publications in cancer research reported the use of the PCT Platform to rapidly breakup tissue samples and release molecules for analysis. PCT's ability to help reveal thousands of proteins from small diagnostic samples, such as cancer tissue biopsies extracted with tiny needles, could result in better understanding of patients' cancers, disease progression, response to therapy, and treatment options. One paper proposed that the PCT Platform could be part of a method that has the potential to accelerate and strengthen protein analysis, improve cancer characterization, and provide clinically relevant information for diagnosis and treatment guidance in a timely manner.
Biomarker Discovery
In addition to cancer biomarker discovery, two papers reported the use of the PCT Platform in studies of biomarkers for cornea, lung and heart disease. Discovery of new biomarkers for early diagnosis, progression, and underlying pathway dysfunction is vital to help improve clinical outcomes. In addition, it was suggested that such biomarkers could serve as possible drug targets.
Food Safety
Four publications described the use PBI's ultra-high pressure platforms to determine conditions forkilling certain bacteria in foods. Recent enhancements in the commercial feasibility of high-pressure processing (HPP) have been pivotal in the development of new methods for ensuring food safety, while preserving important sensory experience and quality factors. We believe that much of the data generated with PBI's high pressure-based instruments will assist food safety researchers worldwide as they consider the use of pressure-based interventions for their microbiological studies.
Protein and Molecular Biology Studies
Several papers reported the use of PCT Platform for proteomic research. The proteome consists of all the proteins made or modified by an organism. Studies of proteins, using PBI's high pressure systems, included protein structure, drug delivery, and diseasestates. The remaining papers covered a range of research including metabolomics, analytical biochemistry, and environmental biology. The papers published in 2018 show the value of PBI's Platform as a general tool for basic research as well as a system for applied studies.
Richard T. Schumacher, President and CEO of PBI, said: "We are very pleased at both the number and wide range of the publications demonstrating the use of our PCT Platform. It is estimated that by 2022, the combined projected market sizes for cancer research, biomarker discovery, and proteomics and molecular biology could be in excess of $250 Billion, with the cancer biomarkers market alone projected to reach $150 Billion. High pressure processing of food is currently estimated to be a multi-billion dollar market. We believe that the credibility gained through scientific papers such as the more than 20 that were published in 2018, and the supportive data and new applications that the authors developed and presented in their publications, will enable PBI to better address these very large and growing markets."
About Pressure BioSciences, Inc.
Over 20 Journal Articles Describe the Advantages of the PCT Platform in Multiple Areas of Research, Including Cancer, Biomarker Discovery, and Food Safety
SOUTH EASTON, MA / ACCESSWIRE / January 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that more than 20 scientific papers citing the advantages of the Company's pressure cycling technology ("PCT" platform were published by independent researchers worldwide in 2018. The publications, authored by scientists from academia, government, and industry, described a wide range of enabling applications for PBI's patented PCT Platform in cancer research, biomarker discovery, and food safety, as well as in proteomic and molecular biology studies. In 2018, a record number of scientific papers highlighting the advantages of PCT over competitive methods were published, authored by researchers in North America, Europe, and Asia. Importantly, a number of these papers were written by scientists considered by many in the life sciences as Key Opinion Leaders ("KOLs"
in their field. High quality papers authored by independent scientists - especially KOLs - and published in well-known, respected journals are an integral part of PBI's marketing strategy. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "We know that scientists have a strong tendency to rely heavily on data and opinions from colleagues and other experts in their field. We therefore enhanced our marketing efforts during the second half of 2018 with a concerted effort to forward this large number of scientific publications to our base of existing and potential customers.We were pleased to see this effort result in increased interest and sales of our Barocycler instruments in 2018, which we believe will continue into 2019 as well."
The 2018 publications were primarily in the following key areas.
Cancer Research
Six publications in cancer research reported the use of the PCT Platform to rapidly breakup tissue samples and release molecules for analysis. PCT's ability to help reveal thousands of proteins from small diagnostic samples, such as cancer tissue biopsies extracted with tiny needles, could result in better understanding of patients' cancers, disease progression, response to therapy, and treatment options. One paper proposed that the PCT Platform could be part of a method that has the potential to accelerate and strengthen protein analysis, improve cancer characterization, and provide clinically relevant information for diagnosis and treatment guidance in a timely manner.
Biomarker Discovery
In addition to cancer biomarker discovery, two papers reported the use of the PCT Platform in studies of biomarkers for cornea, lung and heart disease. Discovery of new biomarkers for early diagnosis, progression, and underlying pathway dysfunction is vital to help improve clinical outcomes. In addition, it was suggested that such biomarkers could serve as possible drug targets.
Food Safety
Four publications described the use PBI's ultra-high pressure platforms to determine conditions forkilling certain bacteria in foods. Recent enhancements in the commercial feasibility of high-pressure processing (HPP) have been pivotal in the development of new methods for ensuring food safety, while preserving important sensory experience and quality factors. We believe that much of the data generated with PBI's high pressure-based instruments will assist food safety researchers worldwide as they consider the use of pressure-based interventions for their microbiological studies.
Protein and Molecular Biology Studies
Several papers reported the use of PCT Platform for proteomic research. The proteome consists of all the proteins made or modified by an organism. Studies of proteins, using PBI's high pressure systems, included protein structure, drug delivery, and diseasestates. The remaining papers covered a range of research including metabolomics, analytical biochemistry, and environmental biology. The papers published in 2018 show the value of PBI's Platform as a general tool for basic research as well as a system for applied studies.
Richard T. Schumacher, President and CEO of PBI, said: "We are very pleased at both the number and wide range of the publications demonstrating the use of our PCT Platform. It is estimated that by 2022, the combined projected market sizes for cancer research, biomarker discovery, and proteomics and molecular biology could be in excess of $250 Billion, with the cancer biomarkers market alone projected to reach $150 Billion. High pressure processing of food is currently estimated to be a multi-billion dollar market. We believe that the credibility gained through scientific papers such as the more than 20 that were published in 2018, and the supportive data and new applications that the authors developed and presented in their publications, will enable PBI to better address these very large and growing markets."
About Pressure BioSciences, Inc.
